11/12/2026

340B ADR Process: A Manufacturer’s Guide to Dispute Resolution

The 340B Drug Pricing Program presents significant compliance and financial challenges for pharmaceutical manufacturers. When a manufacturer believes a covered entity has received duplicate discounts or engaged in diversion, the Administrative Dispute Resolution (“ADR”) process provides a formal administrative mechanism for resolving those disputes. Covered entities can also use the process to bring overcharge claims against manufacturers. This article provides an overview of the ADR process, discusses its practical limitations, and summarizes the legal framework manufacturers should understand before initiating a claim.

Regulations and Requirements

The ADR process is governed by 42 C.F.R. Part 10 and is administered by the Health Resources and Services Administration (“HRSA”) Office of Pharmacy Affairs (“OPA”). It permits manufacturers and covered entities to submit certain disputes for review by an ADR Panel.¹  A manufacturer may file a claim only after it has audited the covered entity under section 340B(a)(5)(C) of the Public Health Service Act. Under HRSA's manufacturer audit guidelines, the audit requires reasonable cause, HRSA review of the audit work plan, and an outside auditor. The manufacturer must also document its good-faith efforts to resolve the dispute with the covered entity before filing.

One of the greatest practical challenges is demonstrating duplicate discounts without access to complete claim-level data. Manufacturers often must rely on indirect evidence from sales, chargeback data, state Medicaid information, and contractual documentation. The lack of clear and consistent links between these data sets can make otherwise valid claims difficult to prove. In evaluating a potential claim, manufacturers should:

  • Complete an internal audit of the covered entity that establishes reasonable cause and supports the claim.
  • Collect relevant evidence, including chargeback records, distribution data, 867 sales data, audit report and findings, and relevant contractual documentation.
  • Engage internal and/or external counsel to support the claim process.
  • Attempt a good-faith resolution directly with the covered entity and maintain written documentation of those communications.

If informal efforts are unsuccessful, manufacturers may consider pursuing a formal ADR claim. Claims should be submitted through HRSA's OPA, including all supporting documentation of good-faith efforts. HRSA provides a detailed procedural overview and workflow on its OPA website.² Absent extenuating circumstances, a claim must be filed in writing with OPA within three years of the date of the alleged violation.³ Although HRSA regulations establish target timeframes for panel review and publication of final agency decisions, actual resolution may take substantially longer depending on the complexity of the dispute.⁴ OPA reviews each claim for completeness and may request additional information, which must be provided within 20 business days or the claim will not go to the ADR Panel. Once the claim is complete, the opposing party has 30 business days to respond. 5

The ADR process is only one component of the broader legal landscape surrounding the 340B Program. Relatively few cases involve manufacturers suing contract pharmacies directly. Instead, litigation has generally focused on two areas: (1) challenges to HRSA or the U.S. Department of Health and Human Services (“HHS”) authority over contract pharmacy policy, and (2) disputes concerning covered-entity compliance with the 340B statute. Recent decisions involving manufacturers such as AstraZeneca, Sanofi, Novo Nordisk, Eli Lilly, and Bristol Myers Squibb illustrate the evolving legal landscape surrounding contract pharmacy restrictions rather than traditional ADR proceedings.

Manufacturer Considerations

Understanding the available dispute resolution mechanisms is only the first step. Manufacturers must also determine how to apply those mechanisms within their own compliance and government pricing processes. The following recommendations provide a practical framework for evaluating potential disputes, preparing supporting evidence, and determining the appropriate path forward for the organization.

  • Establish a consistent identification process. Develop internal procedures for identifying potential duplicate discounts before deciding whether to pursue  an ADR claim.
  • Maintain comprehensive documentation of all communications demonstrating good-faith resolution efforts. Preserve relevant evidence and document communications and efforts to resolve disputes informally.
  • Evaluate whether alternative compliance discussions with the covered entity may resolve the issue more efficiently than formal ADR proceedings.
  • Monitor legal and regulatory developments. Track changes  in HRSA guidance and  relevant federal court decisions, as the legal framework governing 340B disputes continues to evolve.
  • Coordinate legal, government pricing, and compliance teams before initiating an ADR to ensure the supporting evidence is complete and the proposed approach is appropriate for the organization.

As government programs and manufacturer obligations continue to evolve, managing the underlying pricing data, calculations, and financial processes becomes increasingly important. Woven Data's Managed Services support pharmaceutical manufacturers across government pricing, government and commercial rebate processing, payment administration, and gross-to-net management, helping ensure these operations are handled accurately and consistently.

Footnotes
  1. 42 U.S.C. § 256b(d)(3); 42 C.F.R. Part 10, subpart C; 340B Drug Pricing Program; Administrative Dispute Resolution Regulation, 89 Fed. Reg. 28,643 (Apr. 19, 2024) (replacing 85 Fed. Reg. 80,632 (Dec. 14, 2020)).
  2. HRSA Office of Pharmacy Affairs, 340B Administrative Dispute Resolution Process.
  3. 42 C.F.R. § 10.21(b)(1).
  4. 42 C.F.R. §§ 10.24–10.26.
  5. 42 C.F.R. § 10.21(d)(3), (e)(1).

‍

Talk to an Expert

Get Started